Trial NCT04969861

View at ClinicalTrials.gov 
Org. Study IDs: 20-214-36

Last trial update was posted on 2023-01-12

MeSH Interventions

Pembrolizumab

MeSH Conditions

Head and Neck Neoplasms Recurrence

Other Conditions

Metastatic Head and Neck Cancer Recurrent Head and Neck Cancer

Stopping Reasons

Nektar Therapeutics made the decision to discontinue the bempegaldesleukin program based on three negative studies. SFJ Pharmaceuticals, Inc. and Nektar Therapeutics, in consultation with the study IDMC, have decided to discontinue PROPEL-36.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID